COMPASS Pathways plc (CMPS): Business Model Canvas [Dec-2025 Updated]

You're trying to figure out if COMPASS Pathways plc is a near-term commercial success or a long-term bet, and honestly, the late-2025 picture is fascinatingly binary. As an analyst who's seen this movie before, I can tell you they are laser-focused on completing their pivotal Phase 3 trials and getting that New Drug Application filed, all while sitting on $185.9 million in cash as of September 30, 2025, despite burning through $88.5 million in R&D in just nine months. This Business Model Canvas strips away the hype to show you the real engine: the high-touch delivery network they must build and the $0 commercial revenue they currently rely on. Dive in below to see the precise structure supporting this high-stakes journey.

COMPASS Pathways plc (CMPS) - Canvas Business Model: Key Partnerships

You're looking at the network COMPASS Pathways plc has built to move COMP360 from the lab to the clinic and eventually to market. This is where the heavy lifting of clinical execution and future access planning happens.

Academic research institutions for clinical trials are foundational, though specific 2025 data on a Johns Hopkins partnership isn't in the latest filings. However, COMPASS Pathways plc has supported investigator-initiated studies, such as one at The Aquilino Cancer Center at Adventist Healthcare Shady Grove Medical Center, focusing on COMP360 in cancer patients with depression. This support includes funding and training. The company is pioneering a new paradigm, with its Phase 3 program being the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted.

For Contract Research Organizations (CROs) for global Phase 3 trial execution, COMPASS Pathways plc has a long-standing relationship with Worldwide Clinical Trials, which was selected to conduct the major program of late-stage clinical trials for treatment-resistant depression (TRD). The pivotal Phase 3 COMP005 trial, which involved dosing 258 participants with TRD across 32 sites in the United States, achieved its primary endpoint, showing a mean difference in Montgomery-Åsberg Depression Rating Scale (MADRS) scores of -3.6 comparing 25 mg to placebo at week six (p<0.001). The second ongoing pivotal Phase 3 trial, COMP006, has completed enrollment, with 26-week data expected in the second half of 2026.

Strategic collaborations with healthcare systems for future delivery are actively being formed to map out integration. COMPASS Pathways plc established a strategic collaboration with HealthPort, a multi-site comprehensive community health organization, to inform the potential delivery of COMP360 in underserved communities if FDA approved. This is part of a broader effort to integrate COMP360 into different types of US healthcare delivery systems. The company also has collaboration agreements with Hackensack Meridian Health, a large network in New Jersey, and Reliant Medical Group, an Optum company.

The focus on mental health provider networks for training and potential commercial rollout is intensifying, especially following positive Phase 3 data. COMPASS Pathways plc is exploring pathways for an accelerated COMP360 filing for TRD, with commercial launch plans pulled forward by 9-12 months as of October 2025. Key partners in this area include Journey Clinical, a psychedelic-assisted psychotherapy platform, with whom they have a research collaboration agreement to inform therapist training and the delivery model. Other provider network collaborations include Greenbrook TMS and Mindful Health Solutions.

For Patient advocacy groups to inform trial design and access strategies, COMPASS Pathways plc partners with organizations like the American Psychiatric Association Foundation, where they are a Corporate Alliance member, aiming to advance mental health in communities. They also partner with the National Council for Mental Wellbeing to ensure evidence-based innovation is offered safely. The collaboration with HealthPort specifically aims to learn about barriers to equitable access.

Here's a snapshot of some of these key relationships and relevant financial context as of late 2025:

The company's commitment to these partnerships is supported by a cash position of $221.9 million as of June 30, 2025, which is expected to fund operations into 2027. Research and development expenses for the three months ended June 30, 2025, were $30.3 million. COMPASS Pathways plc is currently covered by nine analyst ratings firms, with seven assigning a Buy recommendation.

COMPASS Pathways plc (CMPS) - Canvas Business Model: Key Activities

Completing and analyzing Phase 3 clinical trials for COMP360 in TRD

The COMP005 pivotal trial met its primary endpoint in June 2025, showing a single 25-mg dose of COMP360 reduced symptom severity by 3.6 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 compared to placebo. This trial enrolled 258 patients across 32 sites in the United States. The second Phase 3 trial, COMP006, has completed enrollment with n=585 participants.

Preparing and submitting the New Drug Application (NDA) to the FDA

The company held a positive Type B meeting with the FDA in September 2025 to discuss NDA submission strategies, including the potential for a rolling submission. The potential New Drug Application (NDA) submission timeline is now targeted for late 2026 or early 2027.

Accelerating commercialization readiness plans by 9 to 12 months

COMPASS Pathways plc is accelerating commercial launch plans by 9 to 12 months. The cash position as of September 30, 2025, was $185.9 million. This cash position is projected to fund operating expenses and capital expenditure requirements into 2027.

• Full year 2025 net cash used in operating activities guidance: $120 million to $145 million.
• Cash and cash equivalents as of December 31, 2024: $165.1 million.
• Cash and cash equivalents as of June 30, 2025: $221.9 million.
• Research and development expenses for the three months ended September 30, 2025: $27.3 million.
• Research and development expenses for the nine months ended September 30, 2025: $88.5 million.
• Debt as of September 30, 2025: $31.3 million.

Developing and protecting proprietary intellectual property (IP) for COMP360

As of January 2025, the IP portfolio included over 70 patents on synthetic psilocybin formulations. The company acquired an IP portfolio including patent applications covering a variety of psychedelic and empathogenic substances, with plans to move some new compounds into clinical development within the next two years.

Training therapists and establishing a certified treatment provider network

The therapist training program is designed to include 10 hours of theoretical online learning and Three days of in-person practical skills group training. A research collaboration agreement was established (as of April 2024) with Journey Clinical, which has a network of over 2,000 therapists.

COMPASS Pathways plc (CMPS) - Canvas Business Model: Key Resources

You're looking at the core assets COMPASS Pathways plc (CMPS) is relying on to drive its value proposition in mental health. These aren't just ideas; they're tangible, regulated, and financial anchors. Honestly, in this space, the IP and the cash to fund the trials are everything.

Proprietary Drug Substance and Clinical Program

The absolute linchpin here is the proprietary synthetic psilocybin formulation, COMP360. This isn't just any compound; it's the subject of the largest randomized, controlled, double-blind psilocybin treatment clinical program conducted to date, focused on treatment-resistant depression (TRD). We have concrete efficacy numbers from the first pivotal study, COMP005.

For instance, the top-line data at week 6 showed a mean treatment difference of -3.6 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) when comparing the 25 mg dose of COMP360 versus placebo, with a p-value of p<0.001. That's highly statistically significant. Plus, the second Phase 3 trial, COMP006, has completed enrollment with n=585 participants, meaning the data pipeline is substantial.

Here's a quick look at the key clinical and regulatory milestones underpinning this resource:

• COMP360: Proprietary synthetic psilocybin formulation.
• FDA Status: Holds Breakthrough Therapy designation from the US FDA for TRD.
• COMP005 Data: Achieved primary endpoint at 6 weeks (mean difference -3.6 points, p<0.001).
• COMP006 Enrollment: Completed enrollment of 585 participants.
• Data Durability: Observational follow-up data showed a median time to depressive event of 92 days on a single 25mg administration.

Financial Strength and Runway

You can't run pivotal trials without serious capital. COMPASS Pathways plc has maintained a solid balance sheet to support these expensive, long-duration studies. As of September 30, 2025, the company held $185.9 million in cash and equivalents. That's up from $165.1 million at the end of 2024, showing effective capital management despite ongoing burn.

The expectation for the full year 2025 net cash used in operating activities is set in the range of $120 million to $145 million. What this estimate hides is the timing uncertainty of the UK R&D tax credit, but still, the current cash position is projected to be sufficient to fund operating expenses and capital expenditure requirements into 2027. That runway is a critical resource for near-term operational stability.

Let's map out the key financial figures as of the third quarter close:

Intellectual Property and Regulatory Exclusivity

The global patent portfolio is the moat around COMP360. Patents cover the drug itself, the specific formulation, and the administration methods. As of a recent snapshot, COMPASS Pathways plc held a total of 81 patents globally, with 15 granted, and over 91% of those patents were active. The US is the primary filing location.

Crucially, key US patents, specifically the '257 Patent and '259 Patent, have been upheld, covering the COMP360 crystalline psilocybin polymorph A-the exact polymorph used in their Phase 3 trials. This provides direct protection for the core asset. They also strengthened this by acquiring an IP portfolio in 2021 covering novel psychedelic compounds and prodrugs, expanding the potential pipeline beyond just TRD.

The regulatory status is another non-financial resource that acts as a significant barrier to entry. The Breakthrough Therapy designation from the US FDA for COMP360 in TRD is a major asset, signaling the FDA sees potential for significant improvement over existing therapies. This designation can streamline development and review processes, which is invaluable time saved.

The company's intellectual property assets include:

• Key US patents upheld covering crystalline psilocybin polymorph A.
• A global portfolio of 81 patents (as of April 2023 data).
• Approximately 74 active patents out of the 81 total (as of April 2023 data).
• Acquired IP portfolio covering novel psychedelic compounds and prodrugs.

Finance: draft 13-week cash view by Friday.

COMPASS Pathways plc (CMPS) - Canvas Business Model: Value Propositions

You're looking at the core offering from COMPASS Pathways plc, which centers on delivering a novel, rapid-acting treatment for Treatment-Resistant Depression (TRD) using their investigational COMP360 synthesized psilocybin in conjunction with psychological support. This approach has gained significant regulatory traction, evidenced by the Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and the Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. The speed of effect is a key value driver; for instance, in the Phase 3 COMP005 trial, the clinical effect was observed as early as the day after administration.

The potential for a durable response from a single administration is a major differentiator from daily-dosed antidepressants. Data from an observational follow-up study on a single 25mg administration of COMP360 showed a median time to a depressive event of 92 days (n=252). Furthermore, for the subgroup that continued into the COMP004 long-term extension, this median time extended to 189 days (n=58). This contrasts with the primary endpoint data from the COMP005 Phase 3 trial, which demonstrated a highly statistically significant reduction in symptom severity at six weeks (mean difference of -3.6 points on the MADRS scale versus placebo; p<0.001).

Here's a quick look at the key efficacy and durability metrics we're seeing from COMPASS Pathways plc's data:

This innovation directly addresses a significant unmet need for patients failed by existing antidepressants. TRD is generally defined as an inadequate response to two or more appropriate courses of approved medications. To put the scale in perspective, of the estimated 300 million people globally with Major Depressive Disorder (MDD), approximately one-third are estimated to develop TRD, representing a target population of around 100 million patients worldwide.

The value proposition is further cemented by an integrated care model combining the drug with specialized psychological support, which is critical for psychedelic-assisted therapy. COMPASS Pathways plc is actively exploring real-world implementation through collaborations, such as the one established with HealthPort to inform delivery in underserved communities, focusing on social determinants of health. From a financial standpoint, as of September 30, 2025, the company reported a cash position of $185.9 million, with an expected full-year 2025 net cash used in operating activities in the range of $120 million to $145 million. What this estimate hides is the variability from non-cash adjustments; for the third quarter of 2025, the net loss was $137.7 million, largely driven by a $101.3 million non-cash loss on warrant liabilities. Still, the current cash position is projected to be sufficient to fund operating expenses into 2027.

• Novel treatment for TRD with Breakthrough Therapy designation (US FDA).
• Single administration showing a mean MADRS difference of -3.6 points at 6 weeks (p<0.001).
• Durability potential: Median time to depressive event of 92 days from a single 25mg dose.
• Addresses a market where approximately one-third of MDD patients fail existing treatments.
• Integrated care model being tested via collaborations like the one with HealthPort.
• Cash position of $185.9 million as of September 30, 2025, funding runway into 2027.

COMPASS Pathways plc (CMPS) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so the relationship with the gatekeepers-the providers and regulators-is everything right now. Here's the quick math on how COMPASS Pathways plc is managing those critical connections as of late 2025.

High-touch, specialized engagement with certified treatment providers.

The relationship here is about building the delivery infrastructure before the product is even approved. COMPASS Pathways plc is actively establishing agreements with representative healthcare delivery centers to research scalable commercial rollout models for COMP360, assuming regulatory approval. These collaborations are key to understanding implementation challenges within different systems.

• Strategic collaboration established with HealthPort in April 2025 to inform potential delivery in underserved communities.
• Prior collaboration agreements include Hackensack Meridian Health and Greenbrook TMS (acquired by Neuronetics, Inc. in December 2024).
• The focus is on researching models for scalable, commercial COMP360 treatment delivery within various healthcare settings.

Direct communication with regulatory bodies like the FDA for rolling NDA submission.

Direct, data-driven dialogue with the U.S. Food and Drug Administration (FDA) is paramount for accelerating patient access. The company is moving aggressively on this front following positive trial results.

Building trust through patient advocacy and rigorous, evidence-based research.

Trust is built on delivering on clinical promises. The company has successfully navigated two late-stage studies, which de-risks the program significantly for advocates and future prescribers.

• The COMP005 Phase 3 trial demonstrated a highly statistically significant result for the primary endpoint at 6 weeks.
• The COMP006 Phase 3 trial has 585 enrolled participants.
• The Phase 2b study showed a statistically significant ($\text{p}<0.001$) improvement after three weeks for patients receiving a single 25mg dose of COMP360 with psychological support.

Investor relations to secure ongoing financing for R&D.

Keeping the lights on and the trials funded requires constant, transparent communication with the capital markets. The company is managing its cash burn effectively to maintain its runway.

The company is actively participating in investor conferences, such as those in December 2025, to keep the narrative current. They are defintely focused on demonstrating financial discipline to support the R&D pipeline.

Finance: draft 13-week cash view by Friday.

COMPASS Pathways plc (CMPS) - Canvas Business Model: Channels

The channels for COMPASS Pathways plc are currently split between the ongoing clinical development phase and the accelerated commercial readiness efforts for COMP360 in Treatment-Resistant Depression (TRD).

Global network of clinical trial sites for current drug development.

The current channel for data generation involves a global network of clinical trial sites. The pivotal Phase 3 program for TRD is the largest-to-date randomized, controlled, double-blind psilocybin treatment clinical program ever conducted.

• Enrollment for the second Phase 3 trial, COMP006, has been completed with n=585 participants.
• The Phase 2 study for Post-Traumatic Stress Disorder (PTSD) involved n=22 participants in an open-label safety and tolerability study.
• The company is finalizing the design for a late-stage PTSD trial, with the first patients anticipated in Q1 2026.

Future network of certified treatment centers and clinics.

With commercial launch plans accelerated by 9-12 months, COMPASS Pathways plc is actively preparing the infrastructure for post-approval distribution. The strategy involves leveraging existing infrastructure where possible.

• Sites currently capable of administering SPRAVATO are expected to be able to deliver COMP360, as the physical infrastructure, staffing, and capabilities are largely transferable.
• A strategic collaboration with HealthPort, a multi-site comprehensive community health organization, is in place to inform the potential delivery of COMP360 in underserved communities, if FDA approved.

Direct-to-provider sales force for post-approval distribution.

Commercial preparation activities, including sales force structuring, are being pulled forward by several months. While specific sales force size post-approval isn't detailed, the overall company size provides context for the current operational scale.

• COMPASS Pathways plc had a total of 166 employees as of October 30, 2025.
• Commercial efforts are intensifying with a focus on targeting high-potential prescribers.

Scientific publications and medical conferences to reach prescribers.

Reaching prescribers and key opinion leaders is being executed through data dissemination at scientific forums and investor events.

• The Phase 2 PTSD study findings were published in the September 2025 issue of Journal of Psychopharmacology.
• Management participated in the Stifel 2025 Healthcare Conference on November 11, 2025.
• Management is scheduled to participate in Two Investor Conferences in December.

Here's a quick look at some channel-relevant operational and financial data as of late 2025:

COMPASS Pathways plc (CMPS) - Canvas Business Model: Customer Segments

You're looking at the core groups COMPASS Pathways plc targets as they push COMP360 toward commercialization. This isn't about future potential; this is about the patient populations and providers already engaged in their late-stage development and the financial entities that will ultimately cover the treatment.

Patients with Treatment-Resistant Depression (TRD)

The primary segment is patients with TRD, generally defined as those who haven't adequately responded to at least two or more appropriate courses of approved medications. Honestly, this represents a huge unmet need, as approximately one-third of patients with Major Depressive Disorder (MDD) fall into this category.

The clinical evidence base is built on these patients:

The company is accelerating commercial launch plans by 9-12 months based on these positive results in the TRD population.

Psychiatrists and specialized mental health clinicians

These are the professionals who administer the therapy and will be the gatekeepers for patient access post-approval. They are currently engaged through the clinical trial network and will be the target for specialized training programs.

• The COMP005 trial engaged clinical sites across 32 sites in the United States.
• The FDA granted Breakthrough Therapy Designation for COMP360 in TRD, signaling a high level of interest from regulators in novel treatment pathways for these specialists to adopt.

Training and establishing the necessary infrastructure within these clinics are key to the commercial strategy.

Healthcare systems and payers seeking innovative, cost-effective mental health solutions

This segment includes insurance providers and national health bodies that will determine reimbursement and formulary placement. Their focus is on the long-term economic impact of a treatment that offers rapid and durable responses.

From a financial stability perspective, which underpins future pricing and payer negotiations, COMPASS Pathways plc reported:

• Cash position of $185.9 million as of September 30, 2025.
• Expected full year 2025 net cash used in operating activities in the range of $120 million to $145 million.
• The current cash position is projected to fund operating expenses into 2027.

The successful completion of Phase 3 trials is the direct trigger for engaging these payers on value-based agreements.

Patients in earlier-stage trials for PTSD and anorexia nervosa

While TRD is the immediate focus, the pipeline extends to other serious mental health conditions. The company is actively designing a late-stage development program for Post-Traumatic Stress Disorder (PTSD) based on prior positive Phase 2a results.

The commitment to this segment is reflected in the ongoing R&D spend, with Research and development expenses at $27.3 million for the three months ended September 30, 2025.

COMPASS Pathways plc (CMPS) - Canvas Business Model: Cost Structure

You're looking at the core cash drains for COMPASS Pathways plc as they push their lead asset through late-stage trials and into commercial readiness. For a clinical-stage biotech, the cost structure is heavily weighted toward R&D, which is exactly what the numbers show.

High Research and Development (R&D) expenses are the biggest driver here, totaling $88.5 million for the nine months ended September 30, 2025. This figure reflects the significant investment needed to advance their COMP360 synthetic psilocybin treatment through pivotal Phase 3 clinical trials.

Here's a quick breakdown of the major operating cost components we see in the latest reporting periods:

Clinical trial costs, which are embedded within that R&D spend, cover everything from drug manufacturing for the trials to site management across the COMP005 and COMP006 studies. The increase in R&D year-over-year for the nine months was primarily due to development expenses associated with advancing those late-stage COMP360 phase 3 clinical trials.

General and administrative (G&A) costs for COMPASS Pathways plc, typical for a publicly traded biotech managing regulatory filings and investor relations, saw some fluctuation following a reorganization in late 2024. For the three months ended September 30, 2025, G&A expenses were reported at $13.2 million, down from $15.0 million in the same period of 2024. This decrease was largely due to lower personnel and facility expenses.

Looking at the overall cash burn, the company has provided guidance for the full year 2025 net cash used in operating activities expected to be in the range of $120 million to $145 million. This range includes the timing uncertainty related to the UK R&D tax credit, which is a factor to watch.

To give you a clearer picture of the quarterly G&A trend leading up to the September figure, consider these recent points:

• Three months ended March 31, 2025 G&A: $18.7 million
• Three months ended June 30, 2025 G&A: $12.6 million
• Three months ended September 30, 2025 G&A: $13.2 million

Finance: draft 13-week cash view by Friday.

COMPASS Pathways plc (CMPS) - Canvas Business Model: Revenue Streams

You're looking at the revenue side for COMPASS Pathways plc as of late 2025, and honestly, it's what you'd expect for a company deep in late-stage clinical trials. The core commercial product revenue stream is still theoretical.

• - $0 in commercial product revenue, as the company is pre-commercial.

The actual cash inflows right now come from non-sales activities, primarily from the capital markets and the bank account balances they maintain. Interest income is a direct result of holding significant cash and cash equivalents from prior financing rounds. Here's how that interest income stacked up through the first three quarters of 2025, based on their reported figures (in thousands of US dollars):

That interest income for the nine months ended September 30, 2025, was $5,872 thousand. To give you a sense of scale, that's up from $2,357 thousand for the same nine-month period in 2024. It's not the main event, but it helps offset burn a little.

The biggest non-operating cash inflow event in 2025 was the equity financing that closed around January 2025. This is crucial because it funds the ongoing Phase 3 trials. Here are the hard numbers from that January 2025 offering announcement:

• - Gross proceeds from the offering were expected to be approximately $150 million before deducting underwriting discounts and commissions and other estimated offering expenses.
• - The company could potentially receive up to approximately $353 million in additional gross proceeds if the accompanying ADS Warrants are fully exercised for cash.

You can see the impact of that financing on their balance sheet. Cash and cash equivalents stood at $260.1 million as of March 31, 2025, and then settled at $221.9 million as of June 30, 2025, before dropping further to $185.9 million as of September 30, 2025. That cash position is expected to fund operating expenses and capital expenditure requirements into 2027.

Finally, there's the potential for future, non-dilutive cash from the UK government. COMPASS Pathways plc has indicated that their full-year 2025 net cash used in operating activities guidance, which is a range of $120 million to $145 million, includes the amount receivable in respect of the R&D tax credit in the UK, though the timing for that receipt is uncertain. That tax credit is a future, non-guaranteed inflow that supports the overall cash runway projection.